Questionnaire

1. Haemophilia A is a deficiency of coagulation factor:

2. In patients with haemophilia, approximately what percentage of bleeds are life-threatening?

3. Which of the following joints is most commonly affected by bleeds associated with haemophilia?

4. Which of the following coagulation tests is typically abnormal or prolonged in a patient with haemophilia?

5. In haemophilia A, the aim of treatment for major bleeds is to achieve a plasma FVIII level of:

6. Inhibitors to CFVIII are:

7. Which of the following activated CFs is present in the largest amount in aPCC?

8. Unlike inactivated PCCs, which are mainly used to replace a deficit in CF, aPCC is designed to specifically trigger the clotting process.

9. aPCC is indicated for therapy and prophylaxis of bleeding and to cover surgical intervention in patients with either haemophilia A or B with inhibitors.

10. In the FENOC study including haemophilia patients with inhibitors, the proportion of patients who reported that bleeding had been stopped by treatment with aPCC at 2 hours was

11. Among patients with acquired haemophilia A who were treated with aPCC in real world clinical practice, aPCC stopped bleeding in

12. Among patients with acquired haemophilia A who failed to respond to treatment with rFVIIa, aPCC stopped bleeding in

13. In haemophilia patients with inhibitors who underwent surgery, intraoperative haemostatic efficacy of aPCC was rated as excellent in what percentage of patients?

14. Prophylaxis for severe haemophilia with inhibitors reduces morbidity and improves general health and health-related quality of life (HRQL).

15. In a study of patients with haemophilia A or B with inhibitors, compared with an on-demand regimen, prophylactic use of aPCC was associated with